Related content

Joint pharmacogenomic data submissions guidance released by the US FDA, European Commission and the European Medicines Agency

By  

Pharmacogenomics, Vol. 7, Iss. 5, 2006-07 ,pp. : 659-661

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical case studies

By Trepicchio William L   Williams Grant A   Essayan David   Hall Sue T   Harty Lea C   Shaw Peter M   Spear Brian B   Wang Sue Jane   Watson Mark L  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 519-524

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: non-clinical case studies

By Leighton John K   DeGeorge Joseph   Jacobson-Kram David   MacGregor James   Mendrick Donna   Worobec Alexandra  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 507-511

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

By Ruañño Gualberto   Collins Jerry M   Dorner Andrew J   Wang Sue-Jane   Guerciolini Roberto   Huang Shiew-Mei  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 513-517

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs

By Peters Eric J   Motsinger-Reif Alison   Havener Tammy M   Everitt Lorraine   Hardison Nicholas E   Watson Venita G   Wagner Michael   Richards Kristy L   Province Mike A   McLeod Howard L  

Pharmacogenomics, Vol. 12, Iss. 10, 2011-10 ,pp. : 1407-1415

Future Medicine

Access to resources Recommend Favorite